Q1 2025 EPS Estimates for Haemonetics Co. (NYSE:HAE) Boosted by Zacks Research

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Zacks Research boosted their Q1 2025 earnings per share estimates for shares of Haemonetics in a report released on Tuesday, April 30th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $0.96 for the quarter, up from their prior estimate of $0.95. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.09 EPS and FY2025 earnings at $4.17 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter in the prior year, the business posted $0.85 earnings per share. The business’s quarterly revenue was up 10.1% on a year-over-year basis.

Other analysts have also recently issued reports about the stock. TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Barrington Research restated an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a research report on Friday, April 12th.

Haemonetics Price Performance

NYSE HAE opened at $94.42 on Thursday. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. Haemonetics has a 12 month low of $70.74 and a 12 month high of $95.26. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of 38.38, a PEG ratio of 2.17 and a beta of 0.34. The company’s 50 day moving average is $81.95 and its two-hundred day moving average is $82.74.

Hedge Funds Weigh In On Haemonetics

Several institutional investors have recently bought and sold shares of HAE. Knights of Columbus Asset Advisors LLC grew its position in shares of Haemonetics by 1.3% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier’s stock valued at $896,000 after purchasing an additional 128 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in Haemonetics by 17.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock worth $90,000 after acquiring an additional 156 shares during the last quarter. Riverwater Partners LLC increased its stake in Haemonetics by 1.5% in the 4th quarter. Riverwater Partners LLC now owns 15,784 shares of the medical instruments supplier’s stock worth $1,350,000 after acquiring an additional 231 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Haemonetics by 1.7% during the 3rd quarter. Arizona State Retirement System now owns 14,407 shares of the medical instruments supplier’s stock worth $1,291,000 after acquiring an additional 237 shares in the last quarter. Finally, Contravisory Investment Management Inc. boosted its position in shares of Haemonetics by 7.4% during the 4th quarter. Contravisory Investment Management Inc. now owns 3,507 shares of the medical instruments supplier’s stock valued at $300,000 after acquiring an additional 242 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.